1-2 of 2
Miguel Izquierdo
Close
Sort by
Journal Articles

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Mathias J Rummel, MD PhD, Ann Janssens, David MacDonald, MD FRCPC, Mary-Margaret Keating, MD, Jan Zaucha, MD, Jaclyn Davis, MD, Janet Lasher, Nathalie Lobe, Miguel Izquierdo, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 450.
https://doi.org/10.1182/blood-2018-99-114484
Published: 2018
Journal Articles

Clinical Significance of Myelofibrotic (MF) Changes in Myelodysplastic Syndromes (MDS): A Prospective Evaluation Including Mutational Analysis By Next-Generation Sequencing (NGS)

Fernando Ramos, MDPhDMPH, Cristina Robledo, PhD, Francisco Miguel Izquierdo-García, MDPhD, Dimas Suárez-Vilela, MDPhD, Rocío Benito, PhD, Marta Fuertes, MDPhD, Andrés Insunza, MD, Eva Barragan, PhD, Mónica del Rey, PhD, José María García-Ruiz de Morales, MDPhD, Mar Tormo, MDPhD, Eduardo Salido, MDPhD, Lurdes Zamora, PhD, Carmen Pedro, MD, Javier Sánchez-del-Real, MD, María Díez-Campelo, MD PhD, Consuelo del Cañizo, MD PhD, Guillermo F. Sanz, MD PhD, Jesus Maria Hernández-Rivas, MDPhD
Journal: Blood
Blood (2014) 124 (21): 4652.
https://doi.org/10.1182/blood.V124.21.4652.4652
Published: 2014